Analyst Graig Suvannavejh works at MIZUHO and is focused on the Healthcare sector with 146 price targets and ratings documented since 2018 spanning on 20 stocks. Analyst's average stock valuation to be materialised ratio is 59.17% with an average time for price targets to be met of 90.4 days.
Most recent stock forecast was given on BTAI, BioXcel Therapeutics, Inc at 11-Nov-2022.
Graig Suvannavejh best performing recommendations are on INSM (INSMED INCORPORATED).
The best stock recommendation documented was for INSM (INSMED INCORPORATED) at 2/3/2020. The price target of $33 was fulfilled within 1 day with a profit of $4.12 (14.27%) receiving and performance score of 142.66.
Average potential price target upside
